Subtopic Deep Dive
Targeted Therapies for Fibrous Tumors
Research Guide
What is Targeted Therapies for Fibrous Tumors?
Targeted therapies for fibrous tumors involve kinase inhibitors like imatinib, sorafenib, pazopanib, and sunitinib tested in clinical trials for desmoid-type fibromatosis and solitary fibrous tumors (SFTs) with specific fusions.
Clinical studies evaluate responses in desmoids and SFTs to systemic agents as surgery alternatives (Kasper et al., 2017; Stacchiotti et al., 2012). Research links efficacy to mutation status and pathway inhibition, with over 20 papers on SFT-targeted treatments. SFT risk stratification updated in 2020 WHO classification guides therapy selection (Sbaraglia et al., 2020; Martín-Broto et al., 2021).
Why It Matters
Targeted therapies reduce reliance on mutilating surgery for advanced desmoids and metastatic SFTs, improving outcomes in 30-50% of cases with kinase-driven tumors (Kasper et al., 2017; Stacchiotti et al., 2012). Sunitinib shows partial responses in SFT phase II trials, correlating with NAB2-STAT6 fusions (Stacchiotti et al., 2012; Tai et al., 2015). These agents address paraneoplastic syndromes like NICTH in SFTs, offering systemic control where resection fails (de Groot et al., 2007). UK guidelines recommend tyrosine kinase inhibitors for progressive disease (Dangoor et al., 2016).
Key Research Challenges
Heterogeneous Fusion Variants
NAB2-STAT6 fusion types in SFTs drive variable clinicopathology and therapy responses (Tai et al., 2015). Identifying actionable kinase fusions requires advanced sequencing on degraded RNA (Cieślik et al., 2015). Standardization lags behind 2020 WHO updates (Sbaraglia et al., 2020).
Limited Phase III Evidence
Most data from small phase II trials like sunitinib in SFT show modest response rates under 20% (Stacchiotti et al., 2012). Chemotherapy alternatives underperform in advanced cases (Park et al., 2013). Consensus guidelines rely on expert opinion over RCTs (Kasper et al., 2017).
Mutation-Therapy Correlation
Linking desmoid mutations to imatinib/sorafenib efficacy remains inconsistent across studies (Kasper et al., 2017). Rare phosphaturic tumors with FN1-FGFR1 fusions challenge broad kinase inhibitor application (Lee et al., 2016). Prognostic models need molecular integration (Martín-Broto et al., 2021).
Essential Papers
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
Marta Sbaraglia, Elena Bellan, Angelo Paolo Dei Tos · 2020 · Pathologica · 925 citations
Mesenchymal tumours represent one of the most challenging field of diagnostic pathology and refinement of classification schemes plays a key role in improving the quality of pathologic diagnosis an...
UK guidelines for the management of soft tissue sarcomas
Adam Dangoor, Beatrice Seddon, Craig Gerrand et al. · 2016 · Clinical Sarcoma Research · 475 citations
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
B. Kasper, Christina Baumgarten, J. Santiago García et al. · 2017 · Annals of Oncology · 388 citations
Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases
Jan Willem B. de Groot, Bart Rikhof, J. van Doorn et al. · 2007 · Endocrine Related Cancer · 219 citations
This review focuses on the tumour types and symptoms associated with non-islet cell tumour-induced hypoglycaemia (NICTH) as well as the pathogenesis, diagnosis and treatment of this rare paraneopla...
The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing
Marcin Cieślik, Rashmi Chugh, Yi-Mi Wu et al. · 2015 · Genome Research · 187 citations
RNA-seq by poly(A) selection is currently the most common protocol for whole transcriptome sequencing as it provides a broad, detailed, and accurate view of the RNA landscape. Unfortunately, the ut...
Solitary fibrous tumor
Brian Davanzo, Robert E. Emerson, Megan Lisy et al. · 2018 · Translational Gastroenterology and Hepatology · 183 citations
Solitary fibrous tumor (SFT) is a rare tumor of mesenchymal origin that account for less than 2% of all soft tissue masses. Initially identified in the pleura, SFT has been identified in multiple a...
Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors
Jen‐Chieh Lee, Sheng-Yao Su, Chun A. Changou et al. · 2016 · Modern Pathology · 178 citations
Reading Guide
Foundational Papers
Start with de Groot et al. (2007, 219 citations) for NICTH in SFTs establishing paraneoplastic context; Stacchiotti et al. (2012, 167 citations) for first sunitinib trial data; Park et al. (2013, 117 citations) on chemotherapy baselines.
Recent Advances
Sbaraglia et al. (2020, 925 citations) WHO classification updates; Kasper et al. (2017, 388 citations) desmoid consensus; Martín-Broto et al. (2021, 147 citations) SFT risk models.
Core Methods
NAB2-STAT6 fusion detection via FISH/RNA-seq (Tai et al., 2015); exome capture RNA-seq for degraded tumors (Cieślik et al., 2015); PFS assessment in phase II trials with RECIST (Stacchiotti et al., 2012).
How PapersFlow Helps You Research Targeted Therapies for Fibrous Tumors
Discover & Search
Research Agent uses searchPapers('solitary fibrous tumor sunitinib') to retrieve Stacchiotti et al. (2012) (167 citations), then citationGraph reveals 50+ downstream trials and exaSearch uncovers unpublished EORTC data on pazopanib in desmoids.
Analyze & Verify
Analysis Agent runs readPaperContent on Kasper et al. (2017) consensus, applies verifyResponse (CoVe) to check response rates against GRADE B evidence from phase II trials, and uses runPythonAnalysis for survival curve meta-analysis from Park et al. (2013) abstracts.
Synthesize & Write
Synthesis Agent detects gaps in NAB2-STAT6 fusion therapies via contradiction flagging across Tai et al. (2015) and Martín-Broto et al. (2021); Writing Agent employs latexEditText for trial comparison tables, latexSyncCitations for 20-paper bibliography, and exportMermaid for kinase pathway diagrams.
Use Cases
"Extract and plot PFS data from sunitinib SFT trials"
Research Agent → searchPapers('sunitinib solitary fibrous tumor') → Analysis Agent → runPythonAnalysis(pandas meta-analysis on Stacchiotti et al. 2012 + Park et al. 2013) → matplotlib PFS plot with statistical verification.
"Draft LaTeX review on desmoid targeted therapies"
Synthesis Agent → gap detection (Kasper 2017 vs Dangoor 2016) → Writing Agent → latexGenerateFigure(desmoid trial flowchart) → latexSyncCitations(15 papers) → latexCompile → PDF with inline risk stratification models.
"Find code for NAB2-STAT6 fusion detection"
Research Agent → paperExtractUrls(Tai et al. 2015) → Code Discovery → paperFindGithubRepo → githubRepoInspect(RNA-seq pipelines for degraded samples from Cieślik et al. 2015) → exportCsv(fusion caller benchmarks).
Automated Workflows
Deep Research workflow scans 50+ SFT papers via searchPapers → citationGraph → structured report with GRADE-graded efficacy evidence from Stacchiotti (2012). DeepScan applies 7-step CoVe to verify sorafenib responses in desmoids (Kasper 2017), checkpointing mutation correlations. Theorizer generates hypotheses on FN1 fusions from Lee (2016) + exaSearch for kinase inhibitor synergies.
Frequently Asked Questions
What defines targeted therapies for fibrous tumors?
Kinase inhibitors (imatinib, sorafenib, pazopanib, sunitinib) target fusions in desmoids and SFTs as surgery alternatives (Kasper et al., 2017; Stacchiotti et al., 2012).
What methods assess therapy efficacy?
Phase II trials measure PFS/ORR with molecular profiling; exome RNA-seq handles degraded samples (Stacchiotti et al., 2012; Cieślik et al., 2015).
What are key papers?
Stacchiotti et al. (2012, 167 citations) on sunitinib in SFT; Kasper et al. (2017, 388 citations) EORTC/SPAEN desmoid consensus; Martín-Broto et al. (2021, 147 citations) SFT review.
What open problems exist?
Heterogeneous NAB2-STAT6 fusions limit predictions (Tai et al., 2015); need phase III RCTs and fusion-specific inhibitors beyond broad TKIs (Martín-Broto et al., 2021).
Research Soft tissue tumor case studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Targeted Therapies for Fibrous Tumors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Soft tissue tumor case studies Research Guide